Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.
Volatility and Risk
Larimar Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Altimmune has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500.
Institutional and Insider Ownership
91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Larimar Therapeutics | N/A | N/A | -$80.60 million | ($1.93) | -2.04 |
| Altimmune | $20,000.00 | 20,137.62 | -$95.06 million | ($1.07) | -3.61 |
Larimar Therapeutics has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Larimar Therapeutics and Altimmune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Larimar Therapeutics | N/A | -91.83% | -74.60% |
| Altimmune | -419,575.00% | -54.79% | -47.59% |
Analyst Ratings
This is a breakdown of recent ratings for Larimar Therapeutics and Altimmune, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Larimar Therapeutics | 1 | 0 | 8 | 0 | 2.78 |
| Altimmune | 2 | 1 | 7 | 0 | 2.50 |
Larimar Therapeutics presently has a consensus price target of $16.71, indicating a potential upside of 325.30%. Altimmune has a consensus price target of $16.83, indicating a potential upside of 336.10%. Given Altimmune’s higher probable upside, analysts plainly believe Altimmune is more favorable than Larimar Therapeutics.
Summary
Larimar Therapeutics beats Altimmune on 8 of the 13 factors compared between the two stocks.
About Larimar Therapeutics
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
About Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
